(Q43622984)

25 November 2017

0 references

Oral almotriptan in the treatment of migraine: safety and tolerability (English)

1 reference

25 November 2017

1 reference

Dodick DW

1

1 reference

25 November 2017

1 May 2001

1 reference

25 November 2017

1 reference

25 November 2017

41

1 reference

25 November 2017

5

1 reference

25 November 2017

449-455

1 reference

Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache

25 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

The clinical profile of sumatriptan: safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.01082.X

10.1046/J.1526-4610.2001.01082.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11380642